Lacosamide Fresenius Kabi (Lacosamide)

Lacosamide is an anticonvulsant used in the management of seizure disorders. It acts on neuronal excitability to control epileptic activity.

• Partial‑onset seizures: reduces seizure frequency when used as monotherapy or add‑on therapy.
• Adjunctive therapy for epilepsy: enhances seizure control when combined with other antiepileptic drugs.
• Refractory focal epilepsy: provides additional seizure reduction in patients not adequately controlled by existing regimens.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilizing neuronal membranes and diminishing repetitive neuronal firing. This modulation reduces neuronal excitability, thereby decreasing the likelihood of seizure initiation and propagation in the central nervous system.

Lacosamide may cause a range of adverse reactions. Monitoring patients for both common and serious events is recommended.

Common Side Effects

• Dizziness
• Nausea
• Headache
• Fatigue
• Vision disturbances
• Tremor

Serious or Rare Side Effects

• Cardiac arrhythmia or atrioventricular block
• Severe skin reactions such as Stevens‑Johnson syndrome
• Respiratory depression
• Significant hypotension
• Anaphylactic reactions
• Life‑threatening hepatic injury

Before initiating therapy, clinicians should consider several safety aspects.

• Renal impairment: evaluate renal function and monitor for accumulation.
• Hepatic impairment: use with caution and monitor liver enzymes.
• Concomitant CNS depressants: observe for enhanced sedation.
• Cardiac conduction disorders: obtain baseline ECG and monitor rhythm.
• Pregnancy: risk category unknown; weigh potential benefits against risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lacosamide can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., carbamazepine): may markedly reduce lacosamide levels.
• Class III antiarrhythmics (e.g., amiodarone): increased risk of cardiac conduction abnormalities.
• Other sodium‑channel blockers (e.g., phenytoin): heightened neurotoxicity.
• Monoamine oxidase inhibitors: potential for severe CNS adverse effects.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., erythromycin): may raise plasma concentrations.
• Alcohol: can potentiate central nervous system depression.
• NSAIDs: may affect renal function, especially in patients with pre‑existing renal disease.